Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression
Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, w...
Uloženo v:
| Vydáno v: | Viruses Ročník 15; číslo 1; s. 71 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
MDPI AG
27.12.2022
MDPI |
| Témata: | |
| ISSN: | 1999-4915, 1999-4915 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student’s t-test. Pearson chi-square or Fisher’s exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression. |
|---|---|
| AbstractList | Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student’s t-test. Pearson chi-square or Fisher’s exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression. Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student's -test. Pearson chi-square or Fisher's exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression. Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student's t-test. Pearson chi-square or Fisher's exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression.Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student's t-test. Pearson chi-square or Fisher's exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression. |
| Author | De Vito, Andrea Colpani, Agnese Saderi, Laura Maida, Ivana Sotgiu, Giovanni Madeddu, Giordano Di Castri, Cosimo Fiore, Vito Zauli, Beatrice Fois, Marco Bitti, Alessandra Puci, Mariangela Meloni, Maria Chiara Babudieri, Sergio |
| AuthorAffiliation | 2 Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy 1 Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy |
| AuthorAffiliation_xml | – name: 2 Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy – name: 1 Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy |
| Author_xml | – sequence: 1 givenname: Andrea orcidid: 0000-0002-8265-5400 surname: De Vito fullname: De Vito, Andrea – sequence: 2 givenname: Agnese surname: Colpani fullname: Colpani, Agnese – sequence: 3 givenname: Laura orcidid: 0000-0002-5131-9367 surname: Saderi fullname: Saderi, Laura – sequence: 4 givenname: Mariangela orcidid: 0000-0001-5656-6845 surname: Puci fullname: Puci, Mariangela – sequence: 5 givenname: Beatrice orcidid: 0000-0002-3358-5936 surname: Zauli fullname: Zauli, Beatrice – sequence: 6 givenname: Vito surname: Fiore fullname: Fiore, Vito – sequence: 7 givenname: Marco surname: Fois fullname: Fois, Marco – sequence: 8 givenname: Maria Chiara surname: Meloni fullname: Meloni, Maria Chiara – sequence: 9 givenname: Alessandra surname: Bitti fullname: Bitti, Alessandra – sequence: 10 givenname: Cosimo surname: Di Castri fullname: Di Castri, Cosimo – sequence: 11 givenname: Ivana surname: Maida fullname: Maida, Ivana – sequence: 12 givenname: Sergio orcidid: 0000-0001-7291-8687 surname: Babudieri fullname: Babudieri, Sergio – sequence: 13 givenname: Giovanni orcidid: 0000-0002-1600-4474 surname: Sotgiu fullname: Sotgiu, Giovanni – sequence: 14 givenname: Giordano orcidid: 0000-0001-6099-2273 surname: Madeddu fullname: Madeddu, Giordano |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36680111$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1rFDEYgINU7Ice_AMy4MUexr7J5PMiLGurCwXFVq8hk0m2WWYnazK7sP_ebLcubRE8hITkycP7dYqOhjg4hN5i-Ng0Ci42mAEGEPgFOsFKqZoqzI4enY_Rac4LAM4ViFfouOFcAsb4BE1ny5WxYxV9dWlSv61uJj9u6mn8VZNqMoxhE5Lpq9s7l8xqW8Wh-hyyM9lV31OcJ5dziMNr9NKbPrs3D_sZ-nl1eTv9Wl9_-zKbTq5ry4CMtfTWCUtFy8AqzCnH1kgBQrUUOBMYd542lHpPuAdFmeyM6mzHqOGyBQvNGZrtvV00C71KYWnSVkcT9P1FTHNt0hhs77RSnjTYceKkLQWQ7W5B65invmWUF9envWu1bpeus24YS6JPpE9fhnCn53GjleSM8aYIPjwIUvy9dnnUy5Ct63szuLjOugEKVICS_0eJ4JI0hN6H9f4ZuojrNJSq7ihBFJGMFerd4-APUf9tawHO94BNMefk_AHBoHcjow8jU9iLZ6wNoxlLX0veof_Hjz8uNL6s |
| CitedBy_id | crossref_primary_10_7759_cureus_52096 crossref_primary_10_3390_v15030811 crossref_primary_10_3390_v15081757 crossref_primary_10_7759_cureus_53169 crossref_primary_10_3389_fimmu_2025_1524525 crossref_primary_10_1007_s12325_023_02754_0 crossref_primary_10_3390_v15041025 crossref_primary_10_3390_life13030715 crossref_primary_10_3389_fimmu_2024_1295029 crossref_primary_10_3390_v15112180 crossref_primary_10_1002_jmv_29434 crossref_primary_10_3390_v15040944 crossref_primary_10_3390_life13010183 crossref_primary_10_1080_03007995_2023_2233819 crossref_primary_10_1111_joim_20030 crossref_primary_10_1186_s40001_024_01718_6 crossref_primary_10_3390_vaccines11050896 crossref_primary_10_3390_v15071411 crossref_primary_10_1016_j_jclinepi_2023_04_011 |
| Cites_doi | 10.1056/NEJMoa2021436 10.1089/wound.2020.1309 10.1056/NEJMoa2118542 10.1002/jmv.28011 10.1093/cid/ciac443 10.1016/j.carpath.2020.107228 10.1002/jmv.26016 10.1093/jac/dkac256 10.1097/IPC.0000000000000952 10.1101/2022.08.23.22278585 10.1038/s41586-020-2012-7 10.1371/journal.pone.0248009 10.1038/d41586-021-02483-w 10.1056/NEJMoa2116846 10.1056/NEJMoa2035389 10.1016/S1473-3099(22)00507-2 10.1172/JCI137244 10.1056/NEJMoa2204919 10.1093/cid/ciac781 10.1056/NEJMoa2034577 10.1186/s12929-022-00853-8 10.1016/S0140-6736(22)01586-0 10.1002/hed.26269 10.1016/S1473-3099(20)30402-3 10.1016/j.thromres.2020.04.024 10.1056/NEJMoa2116044 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7U9 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
| DOI | 10.3390/v15010071 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | CrossRef MEDLINE AGRICOLA Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest - Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1999-4915 |
| ExternalDocumentID | oai_doaj_org_article_99f231e62e8c4918b918b0be5f4fb546 PMC9865563 36680111 10_3390_v15010071 |
| Genre | Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACUHS AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK E3Z EBD ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M48 M7P MODMG M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RPM TR2 TUS UKHRP 3V. ALIPV CGR CUY CVF ECM EIF ISR NPM 7U9 7XB 8FK AZQEC COVID DWQXO ESTFP GNUQQ H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c502t-8fce7c47b50c916461ca87079b4065711df4344ff26f09458da9dcd54a68b0c03 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000927190800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1999-4915 |
| IngestDate | Fri Oct 03 12:39:23 EDT 2025 Tue Nov 04 02:06:46 EST 2025 Fri Sep 05 07:24:57 EDT 2025 Thu Oct 02 05:10:13 EDT 2025 Tue Oct 07 06:55:57 EDT 2025 Wed Feb 19 02:26:17 EST 2025 Sat Nov 29 07:13:02 EST 2025 Tue Nov 18 20:52:06 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 antiviral treatment SARS-CoV-2 molnupiravir nirmatrelvir/ritonavir disease progression monoclonal antibody remdesivir vaccination |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-8fce7c47b50c916461ca87079b4065711df4344ff26f09458da9dcd54a68b0c03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5131-9367 0000-0002-3358-5936 0000-0002-1600-4474 0000-0001-7291-8687 0000-0002-8265-5400 0000-0001-5656-6845 0000-0001-6099-2273 |
| OpenAccessLink | https://doaj.org/article/99f231e62e8c4918b918b0be5f4fb546 |
| PMID | 36680111 |
| PQID | 2767292855 |
| PQPubID | 2032319 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_99f231e62e8c4918b918b0be5f4fb546 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9865563 proquest_miscellaneous_3040470983 proquest_miscellaneous_2768232446 proquest_journals_2767292855 pubmed_primary_36680111 crossref_primary_10_3390_v15010071 crossref_citationtrail_10_3390_v15010071 |
| PublicationCentury | 2000 |
| PublicationDate | 20221227 |
| PublicationDateYYYYMMDD | 2022-12-27 |
| PublicationDate_xml | – month: 12 year: 2022 text: 20221227 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Viruses |
| PublicationTitleAlternate | Viruses |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Dolgin (ref_14) 2021; 597 Colpani (ref_24) 2022; 94 Singh (ref_7) 2021; 10 Geremia (ref_8) 2020; 28 Poliseno (ref_17) 2022; 38 ref_30 Geremia (ref_5) 2020; 24 Chi (ref_13) 2022; 29 Piccicacco (ref_31) 2022; 77 ref_19 Musungaie (ref_21) 2022; 386 Wong (ref_25) 2022; 22 Lodigiani (ref_11) 2020; 191 Arbel (ref_22) 2022; 387 Zhou (ref_3) 2020; 579 Hammond (ref_26) 2022; 386 Geng (ref_12) 2020; 47 Chen (ref_2) 2020; 130 Baden (ref_15) 2021; 384 Guarneri (ref_6) 2020; 21 Polack (ref_16) 2020; 383 ref_20 ref_1 Vaira (ref_10) 2020; 42 Mazzitelli (ref_18) 2021; 93 ref_28 ref_27 ref_9 ref_4 Gottlieb (ref_23) 2022; 386 Wong (ref_29) 2022; 400 |
| References_xml | – ident: ref_20 doi: 10.1056/NEJMoa2021436 – volume: 10 start-page: 51 year: 2021 ident: ref_7 article-title: Cutaneous Manifestations of COVID-19: A Systematic Review publication-title: Adv. Wound Care doi: 10.1089/wound.2020.1309 – volume: 24 start-page: 7861 year: 2020 ident: ref_5 article-title: Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 386 start-page: 1397 year: 2022 ident: ref_26 article-title: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2118542 – volume: 94 start-page: 5582 year: 2022 ident: ref_24 article-title: Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: A real-life experience publication-title: J. Med. Virol. doi: 10.1002/jmv.28011 – ident: ref_27 doi: 10.1093/cid/ciac443 – volume: 47 start-page: 107228 year: 2020 ident: ref_12 article-title: Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019 publication-title: Cardiovasc. Pathol. doi: 10.1016/j.carpath.2020.107228 – volume: 93 start-page: 32 year: 2021 ident: ref_18 article-title: use of subcutaneous tocilizumab in patients with COVID-19 pneumonia publication-title: J. Med. Virol. doi: 10.1002/jmv.26016 – volume: 77 start-page: 2693 year: 2022 ident: ref_31 article-title: Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkac256 – volume: 28 start-page: e30 year: 2020 ident: ref_8 article-title: A Case of Vasculitis-Like Skin Eruption Associated With COVID-19 publication-title: Infect. Dis. Clin. Pract. doi: 10.1097/IPC.0000000000000952 – ident: ref_30 doi: 10.1101/2022.08.23.22278585 – volume: 38 start-page: 1 year: 2022 ident: ref_17 article-title: Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: A nested case-control study publication-title: Curr. Med. Res. Opin. – volume: 579 start-page: 270 year: 2020 ident: ref_3 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 – ident: ref_9 doi: 10.1371/journal.pone.0248009 – volume: 597 start-page: 318 year: 2021 ident: ref_14 article-title: The tangled history of mRNA vaccines publication-title: Nature doi: 10.1038/d41586-021-02483-w – volume: 386 start-page: 305 year: 2022 ident: ref_23 article-title: Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2116846 – volume: 384 start-page: 403 year: 2021 ident: ref_15 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 – ident: ref_1 – volume: 22 start-page: 1681 year: 2022 ident: ref_25 article-title: Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: A retrospective cohort study publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(22)00507-2 – volume: 130 start-page: 2620 year: 2020 ident: ref_2 article-title: Clinical and immunologic features in severe and moderate Coronavirus Disease 2019 publication-title: J. Clin. Investig. doi: 10.1172/JCI137244 – volume: 387 start-page: 790 year: 2022 ident: ref_22 article-title: Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2204919 – ident: ref_28 doi: 10.1093/cid/ciac781 – volume: 383 start-page: 2603 year: 2020 ident: ref_16 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – ident: ref_4 – volume: 29 start-page: 82 year: 2022 ident: ref_13 article-title: COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection publication-title: J. Biomed. Sci. doi: 10.1186/s12929-022-00853-8 – volume: 400 start-page: 1213 year: 2022 ident: ref_29 article-title: Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study publication-title: Lancet doi: 10.1016/S0140-6736(22)01586-0 – volume: 42 start-page: 1560 year: 2020 ident: ref_10 article-title: Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study publication-title: Head Neck doi: 10.1002/hed.26269 – volume: 21 start-page: 24 year: 2020 ident: ref_6 article-title: Silent COVID-19: What your skin can reveal publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30402-3 – volume: 191 start-page: 9 year: 2020 ident: ref_11 article-title: Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy publication-title: Thromb. Res. doi: 10.1016/j.thromres.2020.04.024 – ident: ref_19 – volume: 386 start-page: 509 year: 2022 ident: ref_21 article-title: Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients publication-title: New Engl. J. Med. doi: 10.1056/NEJMoa2116044 |
| SSID | ssj0066907 |
| Score | 2.4196332 |
| Snippet | Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 71 |
| SubjectTerms | Age Antibodies, Monoclonal Antiretroviral drugs Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs cohort studies Comorbidity Computed tomography Congestive heart failure Coronaviruses COVID-19 COVID-19 Testing COVID-19 vaccines dementia Dementia disorders Diabetes Diagnosis Disease Disease Progression disease severity Drug dosages Dyspnea Emergency medical care fever glass heart failure Hospitalization Hospitals Humans Immunization Infections Infectious diseases Italy mixed infection molnupiravir Monoclonal antibodies nirmatrelvir/ritonavir oxygen pandemic people Performance evaluation Regression analysis Respiration Retrospective Studies risk Risk assessment Risk factors risk reduction SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistical analysis Supplements t-test Tumors Vaccination |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BAYkL70egIIM4cLGaxI_YJ7QsVHCpVrSg3iLHsUsllJTdbSX-PTNONrCocOGQSzyK7MzDM_bMNwCvKi2bYFzkQmqFAYqouGtzy3X0Om-tEc641GyiOjgwx8d2MR64rca0yo1NTIa67T2dke-VlUY_sDRKvTn7zqlrFN2uji00rsI1QkkQKXVvsbHEmiK_AU1IYGi_d4HODyUFFFt7UILqv8y__DNN8rd9Z__2_874DtwaPU42G0TkLlwJ3T24MfSg_HEf5h9TnSTrI0tgx-xw9umQz_svvGSzjnpL4KTY0QA-wPqOvRuudNiCMrsGVI8H8Hn__dH8Ax87K3Cv8nLNTfSh8rJqVO4tIYwV3hnCymtwf1dVUbRRCiljLHXE-E-Z1tnWt0o6bZrc5-Ih7HR9Fx4DM7bVVgkng0dXxkVLCHsY-UbcBiMarwxeb_517UfYcep-8a3G8IPYUk9syeDlRHo2YG1cRvSWGDYREDx2etEvT-pR22prI_qtQZfBeGkL09CTN0FFGRsldQa7G5bVo86u6l_8yuDFNIzaRlcorgv9eaIx5IPSJ_5GI9AuyipHOc_g0SBB02yF1ugSFLiKaku2tpazPdKdfk2o35ZKiLV48u-pP4WbJRVoFFR0tQs76-V5eAbX_cX6dLV8ntTjJyhvF7c priority: 102 providerName: ProQuest |
| Title | Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36680111 https://www.proquest.com/docview/2767292855 https://www.proquest.com/docview/2768232446 https://www.proquest.com/docview/3040470983 https://pubmed.ncbi.nlm.nih.gov/PMC9865563 https://doaj.org/article/99f231e62e8c4918b918b0be5f4fb546 |
| Volume | 15 |
| WOSCitedRecordID | wos000927190800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: M7P dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Publicly Available Content Database customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1999-4915 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0066907 issn: 1999-4915 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaggMQF8SZQVgZx4BI1id_H7dKKHlhFbUHLKXIcW62EEtRuK_HvmbGzURcVceGQHOyRZc_Ynhl55htCPijJW69tyBmXAhwUpnLbFSaXwcmiM5pZbWOxCbVc6tXK1DdKfWFMWIIHTozbMyaACeJl5bXjptQtfkXrReChFTyCbYPVs3Gm0h0s0edLOEIMnPq9azB7MByg3NI-EaT_NsvyzwDJGxrn8DF5NJqKdJ6m-ITc8f1T8iAVj_z1jCyOYoIjHQKNKMX0ZH58ki-Gb3lF5z0WhYAx6WlCDaBDTz-ltxhaY0hWguN4Tr4eHpwuPudjSYTciaJa5zo4rxxXrSicQWiw0lmNIHctKGahyrILnHEeQiUDOG5Cd9Z0rhPcSuCaK9gLstMPvX9FqDadNIJZ7h3YIDYYhMYDlzWA_gpw62Tk44ZVjRvxwrFsxY8G_AbkajNxNSPvJ9KfCSTjNqJ95PdEgLjWsQGk3YzSbv4l7YzsbqTVjIftsqmUBBeh0kJk5N3UDccE3z5s74erSKPReMQh_kbD4ELjqoANmpGXaQNMs2VSgi4vYRVqa2tsLWe7pz8_i3DdBnN_JXv9P9b_hjysMP-ixJyqXbKzvrjyb8l9d70-v7yYkbtqpeJfz8i9_YNlfTyL52KGIa01tNVHX-rvvwEXsA9p |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL78dCAYNA4hI1iR-xDwgtW6quWlYruqDeQuLYUAklZXdb1D_Fb2QmL1hUuPXAIZdkFMXJ5_E38cw3AM8TJXKnMx9woSQGKDwJsiI0gfJWhYXRPNNZ3WwimUz0wYGZrsGPrhaG0io7n1g76qKy9I98M04U8sBYS_n66FtAXaNod7VrodHAYtedfseQbfFqvIXf90Ucb7-djXaCtqtAYGUYLwPtrUusSHIZWkPqWpHNNOnE5bi2ySSKCi-4EN7HymPsI3WRmcIWUmRK56ENOd73AlxEGhHrOlVw2nl-RZFmo17EuQk3T5BsURJCtLLm1a0BzuKzf6Zl_rbObV__397QDbjWMmo2bKbATVhz5S243PTYPL0No3FdB8oqz2oxZ7Y_fL8fjKqPQcyGJfXOwJfAZo24AqtKttVsWbEpZa41qiV34MO5jOAurJdV6e4D06ZQRvJMOItULfOGFAQxsve4zHt0zgN42X3b1Lay6tTd42uK4RXBIO1hMIBnvelRoyVyltEbAkhvQPLf9Ylq_jltvUlqjEde7lTstBUm0jkdYe6kFz6XQg1go4NI2vqkRfoLHwN42l9Gb0JbRFnpquPaRhPHplv8zYaj3xdJiPN4APcaxPZPy5VCyhPhKJIVLK8MZ_VKefilVjU3VCKt-IN_P_oTuLIze7eX7o0nuw_hakzFKBEVmG3A-nJ-7B7BJXuyPFzMH9dTk8Gn80b6T2ddc0k |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6V8hAX3o9AgQWB1IsV2_vw7gGhkBARFUURLag3Y69320rILkla1L_Gr2PGj0BQ4dYDB1_s0WrX_nYe3plvAF4mSuROZz7gQkkMUHgSZEVoAuWtCgujeaazutlEMp3q_X0z24AfXS0MpVV2OrFW1EVl6R95P04U-oGxlrLv27SI2Wj85vhbQB2k6KS1a6fRQGTHnX3H8G3xejLCb_0qjsfv9obvg7bDQGBlGC8D7a1LrEhyGVpDTFuRzTRxxuVo52QSRYUXXAjvY-UxDpK6yExhCykypfPQhhzHvQSXEyItr9MGZ50VUBR1NkxGnJuwf4qOFyUkRGv2r24TcJ5v-2eK5m82b3zzf35bt-BG62mzQbM1bsOGK-_A1ab35tldGE7q-lBWeVaTPLPdwcfdYFh9DmI2KKmnBr4QtteQLrCqZKPmKIvNKKOtYTO5B58uZAX3YbOsSvcQmDaFMpJnwll04TJviFkQI36P5t-j0u7BdvedU9vSrVPXj68phl0EiXQFiR68WIkeNxwj5wm9JbCsBIgWvL5RzQ_SVsukxnj0152KnbbCRDqnK8yd9MLnUqgebHVwSVtdtUh_YaUHz1ePUcvQ0VFWuuqkltHke9MQf5PhaA9EEuL-7sGDBr2r2XKl0BWKcBXJGq7XlrP-pDw6rNnODZVOK_7o31N_BtcQ4OmHyXTnMVyPqUYlorqzLdhczk_cE7hiT5dHi_nTepcy-HLRQP8JA298Bg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Early+SARS-CoV-2+Antiviral+Therapy+on+Disease+Progression&rft.jtitle=Viruses&rft.au=Andrea+De+Vito&rft.au=Agnese+Colpani&rft.au=Laura+Saderi&rft.au=Mariangela+Puci&rft.date=2022-12-27&rft.pub=MDPI+AG&rft.eissn=1999-4915&rft.volume=15&rft.issue=1&rft.spage=71&rft_id=info:doi/10.3390%2Fv15010071&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_99f231e62e8c4918b918b0be5f4fb546 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon |